Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A type of drug-resistant tuberculosis that is resistant to both rifampicin and isoniazid, the two most powerful anti-TB drugs.
Biomarker and diagnostic research for multidrug-resistant tuberculosis has been reported in the published literature.
9 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, other interventions, and gene therapy. Pipeline includes 1 PHASE4, 3 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05493267](https://clinicaltrials.gov/study/NCT05493267) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:11 PM UTC
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB |
PHASE4 |
Shanghai Pulmonary Hospital, Shanghai, China |
RECRUITING |
[NCT04260477](https://clinicaltrials.gov/study/NCT04260477) | Novel Triple-dose Tuberculosis Retreatment Regimen | PHASE3 | Institute of Tropical Medicine, Belgium | RECRUITING |
[NCT05534750](https://clinicaltrials.gov/study/NCT05534750) | Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) | PHASE2 | Assistance Publique - Hôpitaux de Paris | RECRUITING |
[NCT06700577](https://clinicaltrials.gov/study/NCT06700577) | Multidrug Resistance in Newly Diagnosed TB Patient | — | Assiut University | NOT_YET_RECRUITING |
[NCT01212003](https://clinicaltrials.gov/study/NCT01212003) | Training Protocol on the Natural History of Tuberculosis | — | National Institute of Allergy and Infectious Diseases (NIAID) | RECRUITING |
158 publications have been identified in PubMed for multidrug-resistant tuberculosis. Research spans Epidemiology / Natural History (37%), Basic Science / Preclinical (16%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 58 | 37% |
Laboratory research | 25 | 16% |
Research summaries | 23 | 15% |
Clinical study results | 16 | 10% |
Testing and diagnosis research | 15 | 9% |
New treatment approaches | 11 | 7% |
Patient case studies | 8 | 5% |
Other research | 2 | 1% |
Ishaqui AA (2026). [PMID: 42237966](https://pubmed.ncbi.nlm.nih.gov/42237966/). *Saudi Med J*. [Epidemiology / Natural History]
March VFA (2026). [PMID: 41674995](https://pubmed.ncbi.nlm.nih.gov/41674995/). *JAC Antimicrob Resist*. [Basic Science / Preclinical]
Tristram D (2026). [PMID: 39808063](https://pubmed.ncbi.nlm.nih.gov/39808063/). *Unknown Journal*. [Epidemiology / Natural History]
Hossain A (2026). [PMID: 42010504](https://pubmed.ncbi.nlm.nih.gov/42010504/). *BMC Infect Dis*. [Review / Meta-Analysis]
Zhou Y (2026). [PMID: 41754383](https://pubmed.ncbi.nlm.nih.gov/41754383/). *Pathogens (Basel, Switzerland)*. [Clinical Trial Publication]
Law S (2026). [PMID: 40843468](https://pubmed.ncbi.nlm.nih.gov/40843468/). *Clin Infect Dis*. [Epidemiology / Natural History]
Cebisa M (2026). [PMID: 41900449](https://pubmed.ncbi.nlm.nih.gov/41900449/). *Microorganisms*. [Epidemiology / Natural History]
Ghosh S (2026). [PMID: 42061986](https://pubmed.ncbi.nlm.nih.gov/42061986/). *Life Sci Alliance*. [Diagnostic / Biomarker]
Amiri M (2026). [PMID: 41994187](https://pubmed.ncbi.nlm.nih.gov/41994187/). *IJTLD Open*. [Review / Meta-Analysis]
Pérez-Jacoiste Asín MA (2026). [PMID: 41312401](https://pubmed.ncbi.nlm.nih.gov/41312401/). *JHLT open*. [Case Report / Case Series]
AI-curated news mentioning multidrug-resistant tuberculosis
Updated Sep 9, 2026
A narrative review highlights the diagnostic challenges and management strategies for congenital multidrug-resistant tuberculosis (MDR-TB) in extremely low birth weight neonates. This study underscores the complexities faced in treating this vulnerable population.
A study investigates mutations that confer pyrazinamide resistance in multidrug-resistant tuberculosis isolates from China. Understanding these mutations can inform treatment strategies for this challenging disease.
A multicentre field evaluation of the Xpert MTB/XDR test in sub-Saharan Africa highlights its effectiveness in diagnosing multidrug-resistant tuberculosis. This study contributes to the ongoing efforts to improve tuberculosis management in regions heavily impacted by the disease.
The White House has unveiled the 'National Action Plan to Combat Multidrug-Resistant Tuberculosis (MDR TB)', highlighting the urgent need to address this escalating public health threat. This initiative aims to enhance efforts in finding, curing, and preventing tuberculosis.